<DOC>
	<DOCNO>NCT00471679</DOCNO>
	<brief_summary>RATIONALE : Ethanol-lock treatment may help prevent central venous catheter infection patient high-risk neuroblastoma . PURPOSE : This phase I trial study side effect ethanol-lock treatment prevent central venous catheter infection patient high-risk neuroblastoma .</brief_summary>
	<brief_title>Ethanol-Lock Treatment Preventing Central Venous Catheter Infections Patients With High-Risk Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability ethanol-lock strategy ( ETL ) prevent central venous catheter infection patient high-risk neuroblastoma treat clinical trial MSKCC-03077 . Secondary - Determine whether strategy increase likelihood remain infection-free 6 month . - Determine cumulative incidence single positive centrally-drawn blood culture patient compare previously obtain historical control . - Determine median time-to-infection central line , infection define positive centrally-drawn ( treated line ) blood culture . - Determine cumulative incidence central line removal patient compare historical control . - Collate type organisms among patient develop positive centrally-drawn blood culture compare historical control . OUTLINE : This prospective , nonrandomized , open-label , historical control study . Patients receive monoclonal antibody 3F8 clinical trial MSKCC-03077 . In course monoclonal antibody 3F8 treatment , patient receive ethanol-lock treatment day 0-3 ( monoclonal antibody 3F8 infusion ) 6 month central venous catheter management . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma histopathology OR bone marrow metastases high urine catecholamine level Highrisk disease Currently enrol clinical trial MSKCC03077 Expected duration therapy â‰¥ 6 month Surgicallyimplanted central venous catheter document patency Must able establish patency central venous catheter lumen No history culturepositive central venous catheter infection catheter treat PATIENT CHARACTERISTICS : Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Alkaline phosphatase &lt; 2.5 time ULN No history hypersensitivity ethanol No history document active seizure disorder No document acute liver failure PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent total parenteral nutrition infusion require use central line night No concurrent levetiracetam anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>